Mass spectrometry-based analysis of glycoproteins and its clinical applications in cancer biomarker discovery

被引：33
|
作者：
Liu, Huan [1 ,2 ]
Zhang, Ningbo [1 ,2 ]
Wan, Debin [1 ,2 ]
Cui, Meng [1 ]
Liu, Zhiqiang [1 ]
Liu, Shuying [1 ]
机构：
[1] Chinese Acad Sci, Changchun Inst Appl Chem, Changchun Ctr Mass Spectrometry, 5625 Renmin St, Changchun 130022, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100039, Peoples R China
来源：
CLINICAL PROTEOMICS | 2014年 / 11卷
基金：
中国国家自然科学基金;
关键词：
Mass spectrometry; Glycoproteins; Cancer biomarker; ELECTRON DETACHMENT DISSOCIATION; N-LINKED GLYCOPROTEINS; NANO-LC-MS/MS; STRUCTURAL-CHARACTERIZATION; PROTEIN GLYCOSYLATION; QUANTITATIVE-ANALYSIS; LIVER-CANCER; IDENTIFICATION; SERUM; GLYCANS;
D O I：
10.1186/1559-0275-11-14
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Glycosylation is one of the most important posttranslational modifications of proteins and plays essential roles in various biological processes. Aberration in the glycan moieties of glycoproteins is associated with many diseases. It is especially critical to develop the rapid and sensitive methods for analysis of aberrant glycoproteins associated with diseases. Mass spectrometry (MS) has become a powerful tool for glycoprotein analysis. Especially, tandem mass spectrometry can provide highly informative fragments for structural identification of glycoproteins. This review provides an overview of the development of MS technologies and their applications in identification of abnormal glycoproteins and glycans in human serum to screen cancer biomarkers in recent years.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Mass spectrometry-based analysis of glycoproteins and its clinical applications in cancer biomarker discovery
    Huan Liu
    Ningbo Zhang
    Debin Wan
    Meng Cui
    Zhiqiang Liu
    Shuying Liu
    Clinical Proteomics, 2014, 11
  • [2] Mass Spectrometry-Based Glycoproteomic Workflows for Cancer Biomarker Discovery
    Doud, Emma H.
    Yeh, Elizabeth S.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [3] Advances in mass spectrometry-based clinical biomarker discovery
    Crutchfield, Christopher A.
    Thomas, Stefani N.
    Sokoll, Lori J.
    Chan, Daniel W.
    CLINICAL PROTEOMICS, 2016, 13
  • [4] Mass Spectrometry-based Quantitative Analysis and Biomarker Discovery
    Suzuki, Naoto
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2011, 131 (09): : 1305 - 1309
  • [5] Mass spectrometry-based membrane proteomics in cancer biomarker discovery
    Mermelekas, George
    Zoidakis, Jerome
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (05) : 549 - 563
  • [6] Mass Spectrometry-Based Approaches for Clinical Biomarker Discovery in Traumatic Brain Injury
    Creech, Matthew
    Carvalho, Lindsey
    McCoy, Heather
    Jacobs, Jon
    Hinson, H. E.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2022, 24 (12) : 605 - 618
  • [7] Advances in mass spectrometry-based clinical biomarker discovery
    Christopher A. Crutchfield
    Stefani N. Thomas
    Lori J. Sokoll
    Daniel W. Chan
    Clinical Proteomics, 2016, 13
  • [8] Biomarker discovery in mass spectrometry-based urinary proteomics
    Thomas, Samuel
    Hao, Ling
    Ricke, William A.
    Li, Lingjun
    PROTEOMICS CLINICAL APPLICATIONS, 2016, 10 (04) : 358 - 370
  • [9] Mass Spectrometry-Based Glycoproteomic Workflows for Cancer Biomarker Discovery
    Doud, Emma H.
    Yeh, Elizabeth S.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [10] Mass spectrometry-based tissue proteomics for cancer biomarker discovery
    Baigley, Brian M.
    Wang, Weijie
    De Voe, Don L.
    Lee, Cheng S.
    PERSONALIZED MEDICINE, 2007, 4 (01) : 45 - 58
12345